EcoDrugPlus

Neuronal Acetylcholine Receptor Subunit Alpha-2-Like

Ensembl ID : ENSCMIG00000004614
Gene Symbol: LOC103172408
3 Cross references
206 Possible Orthologues:

Neuronal Acetylcholine Receptor Subunit Beta-2-Like

Ensembl ID : ENSCMIG00000004691
Gene Symbol: LOC103173104
2 Cross references
263 Possible Orthologues:

Neuronal Acetylcholine Receptor Subunit Beta-4-Like

Ensembl ID : ENSCMIG00000008145
Gene Symbol: LOC103188367
2 Cross references
199 Possible Orthologues:

Neuropeptide Y Receptor Y2, Like

Ensembl ID : ENSCMIG00000010294
Gene Symbol: NPY2RL
1 Cross references
248 Possible Orthologues:

Neuropeptide Y Receptor Y5

Ensembl ID : ENSCMIG00000009183
Gene Symbol: NPY5R
3 Cross references
137 Possible Orthologues:

Neuropeptide Y Receptor Type 1-Like

Ensembl ID : ENSCMIG00000000995
Gene Symbol: LOC103181138
3 Cross references
116 Possible Orthologues:

Neurotensin Receptor 1

Ensembl ID : ENSCMIG00000015551
Gene Symbol: NTSR1
4 Cross references
208 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 2

Ensembl ID : ENSCMIG00000014026
Gene Symbol: NTRK2
3 Cross references
288 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSCMIG00000011295
Gene Symbol: NTRK3
3 Cross references
271 Possible Orthologues:

Nicotinamide Phosphoribosyltransferase

Ensembl ID : ENSCMIG00000014905
Gene Symbol: NAMPT
4 Cross references
235 Possible Orthologues:

Nitric Oxide Synthase 2

Ensembl ID : ENSCMIG00000010747
Gene Symbol: NOS2
4 Cross references
168 Possible Orthologues:

Notch Receptor 1

Ensembl ID : ENSCMIG00000000648
Gene Symbol: NOTCH1
3 Cross references
268 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).